Time in Range in 2026: Moving From Metric to Treatment Target

Continuous glucose monitoring has transformed diabetes care, but are we fully using the data it provides? In 2026, time in range is moving beyond a simple CGM metric and becoming a formal therapeutic target in diabetes care. While A1C remains important, time in range (TIR) offers a more dynamic and patient-centered view of glycemic control. As technology becomes routine in both type 1 and type 2 diabetes, the challenge is no longer access to data. Instead, the focus is on integrating time in range into treatment algorithms and everyday clinical decisions.

Table of Contents

• Why Time in Range Matters in 2026
• Correlation Between TIR and Microvascular Outcomes
• Expanding TIR Beyond Insulin Users
• Using TIR for Intensification and De-Intensification
• FAQs

Why Time in Range Matters in 2026

Time in range refers to the percentage of time a person’s glucose levels remain within a target range, typically 70–180 mg/dL. Although A1C reflects average glucose over three months, it does not capture variability, hypoglycemia, or daily glucose patterns. Therefore, TIR adds clinical depth that A1C alone cannot provide.

In 2026, many experts emphasize that every 10% increase in time in range corresponds to meaningful improvements in glycemic stability. For example, a patient with 70% TIR spends roughly 17 hours per day within target glucose levels. In contrast, someone at 50% TIR spends nearly five additional hours daily outside the optimal range. Over weeks and months, that difference adds up.

Moreover, time in range resonates with patients. People understand “time spent in range” more easily than abstract percentages like A1C. As a result, shared decision-making becomes more actionable. According to the American Diabetes Association Standards of Care, CGM metrics such as TIR should complement A1C in guiding therapy adjustments. However, adoption into formal treatment pathways remains inconsistent across practices.

Correlation Between TIR and Microvascular Outcomes

One of the strongest arguments for elevating time in range to a treatment target in 2026 is its association with complications. Emerging evidence suggests that higher TIR correlates with lower rates of retinopathy and microalbuminuria. While long-term randomized data are still evolving, observational analyses show consistent trends.

Studies evaluating CGM metrics alongside retinal imaging have demonstrated that lower time in range aligns with greater risk of diabetic retinopathy progression. Similarly, reduced TIR has been associated with early nephropathy markers. These findings reinforce what we have long understood about cumulative hyperglycemia exposure. However, time in range captures that exposure in a more granular and actionable way.

Importantly, TIR also reflects hypoglycemia risk. Two patients with identical A1C values may have very different glucose variability profiles. One may experience frequent lows offset by highs, while the other maintains stable readings throughout the day. In this context, time in range provides a clearer and more clinically useful picture of daily glycemic burden.

Expanding TIR Beyond Insulin Users

Initially, continuous glucose monitoring was primarily used in patients with type 1 diabetes or those on intensive insulin regimens. However, in 2026, conversations about time in range increasingly include people with type 2 diabetes using GLP-1 receptor agonists such as semaglutide (Ozempic) or dual GIP/GLP-1 agents like tirzepatide (Mounjaro).

Even for individuals who are not adjusting rapid-acting insulin doses, CGM can reveal postprandial excursions and overnight patterns that A1C misses. Therefore, time in range becomes a tool for lifestyle optimization and medication fine-tuning. For example, adjusting meal timing, carbohydrate intake, or adding an SGLT2 inhibitor may meaningfully improve TIR without increasing hypoglycemia risk.

Furthermore, intermittent CGM use can support behavioral change. Short-term sensor wear allows patients to visualize how physical activity, stress, or dietary choices influence glucose trends. As a result, time in range serves not only as a clinical metric but also as a motivational instrument that supports patient engagement.

Using TIR for Intensification and De-Intensification

The most important shift in 2026 is conceptual: time in range is no longer just descriptive. Instead, it is becoming a practical guide for both therapy intensification and thoughtful de-intensification.

For patients with persistently low TIR and significant hyperglycemia, treatment intensification is appropriate. That may involve optimizing basal insulin, adding prandial insulin, or introducing agents such as GLP-1 receptor agonists. However, clinicians can now target specific CGM patterns rather than relying solely on quarterly A1C values.

Conversely, high time in range accompanied by frequent hypoglycemia may signal overtreatment. In older adults or those with multiple comorbidities, careful de-intensification may reduce risk without sacrificing meaningful glycemic control. Therefore, TIR supports individualized targets aligned with life expectancy, cardiovascular risk, and patient preference.

As healthcare systems move toward value-based care, measurable CGM outcomes may complement traditional A1C benchmarks. Over time, standardized time in range goals could influence payer policies and performance metrics. Nevertheless, broader integration requires improved EHR compatibility and ongoing clinician education in ambulatory glucose profile interpretation.

Conclusion

In 2026, time in range represents a pivotal evolution in diabetes management. While A1C remains a cornerstone, TIR provides a more nuanced and patient-centered assessment of glycemic control. Evidence linking higher time in range with reduced microvascular risk continues to grow. At the same time, expanding CGM use beyond insulin therapy broadens its clinical relevance.

Most importantly, time in range now informs both therapy intensification and safe de-intensification. As integration into treatment algorithms improves, clinicians can use TIR not just to observe glucose patterns, but to actively shape them. The transition from metric to treatment target is well underway.

FAQs

What is the recommended time in range goal for most adults with diabetes?
For many nonpregnant adults, a target of at least 70% time between 70–180 mg/dL is recommended. However, goals should always be individualized based on age, comorbidities, and hypoglycemia risk.

Does time in range replace A1C testing?
No. Time in range complements A1C but does not replace it. Both metrics provide valuable and sometimes different insights into glycemic control.

Is time in range useful for people with type 2 diabetes not using insulin?
Yes. CGM and TIR can reveal glucose variability, post-meal spikes, and lifestyle effects, even in patients using medications such as Ozempic or Mounjaro.

How often should clinicians review time in range data?
Ideally, TIR should be reviewed at each clinical encounter when CGM data are available. More frequent review may be helpful during therapy adjustments.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.